Von Hippel Lindau/VHL Antibody (B-9): sc-514959
- Von Hippel Lindau/VHL Antibody (B-9) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- specific for an epitope mapping between amino acids 157-181 at the C-terminus of VHL of rat origin
- recommended for detection of VHL of mouse and rat origin by WB, IP, IF and ELISA
- See Von Hippel Lindau/VHL (D-7): sc-55506 for Von Hippel Lindau/VHL antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for Von Hippel Lindau/VHL Antibody (B-9) for WB applications. These reagents are now offered in bundles with Von Hippel Lindau/VHL Antibody (B-9) (see ordering information below).
QUICK LINKS
SEE ALSO...
VHL Antibody (B-9) is a mouse monoclonal IgG1 antibody that detects von Hippel-Lindau (VHL) in mouse and rat samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-VHL antibody (B-9) plays a crucial role in understanding the function of VHL, which is a key tumor suppressor involved in the regulation of hypoxia-inducible factors (HIFs). By targeting the Elongin (SIII) complex, VHL modulates the transcriptional activity of genes that respond to oxygen levels, thereby influencing cellular responses to hypoxia. This regulation is vital for maintaining cellular homeostasis and preventing tumorigenesis, as dysregulation of HIFs can lead to increased angiogenesis and tumor growth. The presence of different isoforms of VHL, which arise from alternatively spliced transcript variants, adds complexity to its function and regulation, as these isoforms may exhibit distinct roles in cellular processes. VHL monoclonal antibody (B-9) is an essential tool for researchers investigating the molecular mechanisms underlying VHL-related pathologies and the broader implications of hypoxia in cancer biology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Von Hippel Lindau/VHL Antibody (B-9) References:
- VHL and HIF signalling in renal cell carcinogenesis. | Baldewijns, MM., et al. 2010. J Pathol. 221: 125-38. PMID: 20225241
- Role of VHL gene mutation in human renal cell carcinoma. | Arjumand, W. and Sultana, S. 2012. Tumour Biol. 33: 9-16. PMID: 22125026
- VHL Synthetic Lethality Signatures Uncovered by Genotype-Specific CRISPR-Cas9 Screens. | Sun, N., et al. 2019. CRISPR J. 2: 230-245. PMID: 31436504
- Control of Angiogenesis via a VHL/miR-212/132 Axis. | Lei, Z., et al. 2020. Cells. 9: PMID: 32325871
- Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. | Chahoud, J., et al. 2021. World J Urol. 39: 2409-2415. PMID: 32936333
- First HIF-2 antagonist for VHL tumors. | . 2021. Nat Biotechnol. 39: 1032. PMID: 34504344
- Targeted Degradation of mRNA Decapping Enzyme DcpS by a VHL-Recruiting PROTAC. | Swartzel, JC., et al. 2022. ACS Chem Biol. 17: 1789-1798. PMID: 35749470
- Potential Role of VHL, PTEN, and BAP1 Mutations in Renal Tumors. | Szegedi, K., et al. 2023. J Clin Med. 12: PMID: 37445575
- Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBC. | Karpińska, K., et al. 2024. J Med Chem. 67: 15012-15028. PMID: 39207123
- A case of ovarian mesothelioma with VHL mutation diagnosed by immunohistochemistry and literature review. | Yao, Y., et al. 2024. Front Oncol. 14: 1471978. PMID: 39605894
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Von Hippel Lindau/VHL Antibody (B-9) | sc-514959 | 200 µg/ml | $322.00 | |||
Von Hippel Lindau/VHL Antibody (B-9): m-IgG Fc BP-HRP Bundle | sc-541017 | 200 µg Ab; 10 µg BP | $361.00 | |||
Von Hippel Lindau/VHL Antibody (B-9): m-IgG1 BP-HRP Bundle | sc-542532 | 200 µg Ab; 20 µg BP | $361.00 | |||
Von Hippel Lindau/VHL (B-9) Neutralizing Peptide | sc-514959 P | 100 µg/0.5 ml | $69.00 |